AUTHORS
Mavis Obeng-Kusi, PhD, Xiaoqin Yang, PhD2, Francesca Coutinho3, Rose Chang4, Priyanka Bobbili, MS, ScD5, Louise Clear6, Alexandra Barry7, Joanne Chukwueke8, Mei Sheng Duh, ScD, MPH9, Evan C. Chen, MD10
AFFILIATIONS
1 Merck & Co., Inc., Rahway, United States
2 Merck & Co., Inc., Rahway, United States
3 Merck & Co., Inc., Rahway, United States
4 Analysis Group, Inc., Boston, United States
5 Analysis Group, Inc., Boston, United States
6 Analysis Group, Inc., Boston, United States
7 Analysis Group, Inc., Boston, United States
8 Analysis Group, Inc., Boston, United States
9 Analysis Group, Inc., Boston, United States
10 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
ABSTRACT
Introduction:
Essential thrombocythemia (ET) is a rare chronic myeloproliferative neoplasm characterized by elevated platelet counts, thrombotic and bleeding complications, and risk of progression to myelofibrosis (MF) or blast phase disease. Although cytoreductive therapy (CRT) is recommended for high-risk and symptomatic intermediate-risk patients, substantial clinical burden may persist. Real-world evidence describing clinical outcomes, healthcare resource utilization (HCRU) and costs following initiation of CRT remains limited.
Objective:
To characterize ET complications including thrombotic and bleeding outcomes and assess all-cause and ET-related HCRU and costs among patients with ET treated with CRT.
Methods:
Adult patients with ET treated with CRT were identified from the Humana Research Database from January 2012 to September 2025. Eligible patients had ≥2 claims with an ICD-9/10 ET diagnosis code, ≥1 of which was associated with a visit with a hematology/oncology specialist; continuous health plan eligibility ≥ 6 months before and ≥ 3 months after the first ET diagnosis claim; and a prescription for CRT on or after first ET diagnosis.
The index date was defined as the prescription date of the first (1L) CRT for ET. Clinical outcomes, including thrombotic and bleeding events, and all-cause and ET-related HCRU and costs were assessed from index date to the earliest of transformation to MF or blast phase disease, end of continuous eligibility, death, or end of data availability. Kaplan-Meier (KM)-estimated 1- and 2-year cumulative incidence rates for thrombotic and bleeding events were calculated. Major bleeding events were defined using modified International Society on Thrombosis and Haemostasis criteria. ET-related HCRU and costs were defined based on claims with a diagnosis code for ET, thrombotic events, or major bleeding events. HCRU and costs were also described among the subgroup of patients who experienced any thrombotic or major bleeding events during follow-up.
Results:
Among 3,207 patients identified, median age at index date was 74.7 years, 63.7% were female, 77.7% were White, 99.2% were Medicare Advantage insured, and 19.9% had a history of thrombosis in the 6 months pre-index. Hydroxyurea was the predominant 1L therapy (94.1%). Over a median (range) follow-up of 2.0 (0.7, 4.3) years after index date, 23.2% experienced a thrombotic event with cumulative incidences of 11.5% at 1 year and 18.7% at 2 years. Major bleeding events occurred in 4.6% of patients, with cumulative incidences of 1.6% at 1 year and 2.9% at 2 years.
The clinical burden of ET patients treated with CRT is reflected by substantial all-cause HCRU and costs. Nearly all patients (99.1%) had outpatient visits, 56.8% had emergency department (ED) visits, and 46.3% had inpatient (IP) admissions. Mean all-cause care visits were 2.4 IP, 1.4 ED, and 42.7 OP visits per-person-per-year (PPPY). Mean all-cause medical costs were $29,680 PPPY, of which a significant proportion was ET-related. Mean ET-related visits were 1.3 IP, 0.7 ED, and 17.2 OP visits PPPY, and mean ET-related medical costs were $10,632 PPPY (representing 35.8% of all-cause costs). More specifically, ET-related costs represented 41.5% of all-cause IP costs, 49.2% of all-cause ED costs, and 29.5% of all-cause OP costs PPPY.
Among 799 (24.9%) ET patients with a thrombotic or bleeding event, most HCRU and costs appear to be higher: mean all-cause visits were 3.1 IP, 2.2 ED, and 35.6 OP visits PPPY, and mean all-cause medical costs were $46,623 PPPY, largely driven by inpatient care ($31,642). Mean ET-related costs among patients with a thrombotic or bleeding event were $20,535 PPPY, representing 44.0% of their all-cause medical costs and nearly double the ET-related costs observed in the overall treated cohort ($10,632 PPPY).
Conclusions:
In this large real-world claims-based analysis, nearly one-quarter experienced a thrombotic or major bleeding event, and ET-related care accounted for a meaningful share of overall HCRU and costs. The burden was particularly pronounced among patients with ET complications including thrombotic or bleeding events, who had higher IP and ED use and nearly double the ET-related costs observed in the overall treated cohort. These findings underscore the substantial clinical and economic burden among ET patients treated with CRT and highlight the unmet need for novel ET therapies.
DISCLOSURES
Evan C. Chen, MD: Syndax - Research Funding; Arcellx - Research Funding; Takeda - Research Funding; AbbVie - Research Funding; Merck & Co., Inc. - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony)